Weil Company Inc. Boosts Stock Holdings in Illumina, Inc. $ILMN

Weil Company Inc. raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 13.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,941 shares of the life sciences company’s stock after acquiring an additional 2,779 shares during the period. Weil Company Inc.’s holdings in Illumina were worth $2,284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Illumina by 3.5% in the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock worth $1,298,928,000 after buying an additional 558,243 shares during the period. WCM Investment Management LLC increased its holdings in Illumina by 5.9% during the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after buying an additional 247,460 shares during the period. Corvex Management LP raised its position in shares of Illumina by 125.2% in the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after acquiring an additional 2,129,449 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Illumina by 361.7% during the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock worth $165,484,000 after acquiring an additional 1,662,093 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Illumina by 51.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock valued at $155,537,000 after purchasing an additional 667,978 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of ILMN opened at $121.72 on Tuesday. The stock has a market cap of $18.60 billion, a PE ratio of 15.41, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $153.06. The firm has a fifty day moving average price of $100.95 and a 200 day moving average price of $94.88.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research reports. Daiwa America lowered Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. Barclays upped their price target on Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a report on Friday, October 31st. Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a research report on Tuesday, September 2nd. Canaccord Genuity Group boosted their price target on Illumina from $105.00 to $112.00 and gave the stock a “hold” rating in a research report on Friday, October 31st. Finally, Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $115.00.

Insider Transactions at Illumina

In other Illumina news, Director Scott Gottlieb acquired 500 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 2.60% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.